Cytosorbents Co. (NASDAQ:CTSO) COO Vincent Capponi sold 28,000 shares of the stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $10.00, for a total transaction of $280,000.00. Following the sale, the chief operating officer now directly owns 325,551 shares in the company, valued at $3,255,510. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Vincent Capponi also recently made the following trade(s):
- On Tuesday, May 15th, Vincent Capponi sold 7,154 shares of Cytosorbents stock. The shares were sold at an average price of $9.00, for a total transaction of $64,386.00.
Shares of CTSO stock opened at $10.55 on Monday. Cytosorbents Co. has a one year low of $3.30 and a one year high of $10.90. The company has a current ratio of 6.16, a quick ratio of 5.99 and a debt-to-equity ratio of 0.68.
Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Thursday, March 8th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The company had revenue of $4.65 million for the quarter, compared to analysts’ expectations of $4.56 million. Cytosorbents had a negative net margin of 56.06% and a negative return on equity of 88.39%. sell-side analysts forecast that Cytosorbents Co. will post -0.46 earnings per share for the current fiscal year.
Several brokerages recently commented on CTSO. BidaskClub raised shares of Cytosorbents from a “hold” rating to a “buy” rating in a research report on Thursday. Maxim Group set a $13.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research report on Tuesday, May 15th. ValuEngine raised shares of Cytosorbents from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 12th. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Cytosorbents in a research report on Wednesday, May 9th. Finally, Cowen set a $9.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research report on Thursday, March 8th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $11.25.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC boosted its holdings in shares of Cytosorbents by 134.4% during the 1st quarter. Millennium Management LLC now owns 384,330 shares of the medical research company’s stock valued at $2,710,000 after acquiring an additional 220,353 shares during the last quarter. B. Riley Financial Inc. purchased a new stake in shares of Cytosorbents during the 4th quarter valued at about $992,000. Raymond James & Associates boosted its holdings in shares of Cytosorbents by 100.0% during the 4th quarter. Raymond James & Associates now owns 100,000 shares of the medical research company’s stock valued at $650,000 after acquiring an additional 50,000 shares during the last quarter. PEAK6 Investments L.P. boosted its holdings in shares of Cytosorbents by 13.7% during the 4th quarter. PEAK6 Investments L.P. now owns 99,744 shares of the medical research company’s stock valued at $648,000 after acquiring an additional 12,022 shares during the last quarter. Finally, BlueCrest Capital Management Ltd purchased a new stake in shares of Cytosorbents during the 4th quarter valued at about $396,000. 13.13% of the stock is currently owned by hedge funds and other institutional investors.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.